

New Sterols and Triterpenoids from Four Edible Mushrooms¹⁾

Yasunori YAOITA, Kaori MATSUKI, Takeyoshi IJIMA, Satomi NAKANO, Rie KAKUDA, Koichi MACHIDA, and Masao KIKUCHI*

Tohoku Pharmaceutical University, 4-1 Komatsushima 4-chome, Aoba-ku, Sendai, Miyagi 981-8558, Japan.

Received November 29, 2000; accepted January 15, 2001

Four edible mushrooms, *Panellus serotinus*, *Lepista nuda*, *Tricholoma matsutake* and *Naematoloma sublateritium*, have been investigated chemically. Two new sterols, 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 α -diol (1) and 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 β -diol (2), have been isolated from *Panellus serotinus*. Compound 2 was also isolated from *Lepista nuda*. A new sterol, 3 β ,5 α ,9 α ,14 β -tetrahydroxy-(22*E*)-ergosta-7,22-dien-6-one (3), and compound 2 have been isolated from *Tricholoma matsutake*. Three new triterpenoids, sublateriols A–C (4–6), have been isolated from *Naematoloma sublateritium*. The structures of the new compounds were elucidated on the basis of their spectral data.

Key words sterol; triterpenoid; mushroom

Recently we reported the isolation and structural elucidation of sterols,²⁾ sesquiterpenoids,^{1,3)} triterpenoids,¹⁾ and ceramides⁴⁾ from fourteen mushrooms. In a continuation of our investigation of the chemical constituents from mushrooms, we describe here the isolation and structural elucidation of three new sterols, 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 α -diol (1), 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 β -diol (2) and 3 β ,5 α ,9 α ,14 β -tetrahydroxy-(22*E*)-ergosta-7,22-dien-6-one (3), and three new triterpenoids, sublateriols A–C (4–6), as well as eighteen known compounds, (22*E*)-ergosta-5,7,9(11),22-tetraen-3 β -ol (7),^{2c,5)} ergosterol (8),^{2f,6)} (22*E*)-ergosta-5,8,22-trien-3 β -ol (9),^{2c,7)} ergosta-5,7-dien-3 β -ol (10),^{2c,6)} (22*E*)-ergosta-7,22-dien-3 β -ol (11),^{2c,8)} ergost-7-en-3 β -ol (12),^{2c,6)} 5 α ,8 α -epidioxy-(22*E*)-ergosta-6,22-dien-3 β -ol (13),^{2a,9)} 5 α ,6 α :8 α ,9 α -diepoxy-(22*E*)-ergost-22-ene-3 β ,7 α -diol (14),^{2e)} 5 α ,9 α -epidioxy-3 β -hydroxy-(22*E*)-ergosta-7,22-dien-6-one (15),^{2b)} 3 β ,5 α ,9 α ,14 α -tetrahydroxy-(22*E*)-ergosta-7,22-dien-6-one (16),^{2b)} 3 β ,5 α ,9 α -trihydroxy-(22*E*)-ergosta-7,22-dien-6-one (17),^{2a,10)} 3 β ,5 α ,9 α -tetrahydroxyergost-7-en-6-one (18),^{2b)} (22*E*)-ergosta-7,22-diene-3 β ,5 α ,6 β -triol (19),^{2a,11)} ergost-7-ene-3 β ,5 α ,6 β -triol (20),^{2b,12)} (22*E*)-ergosta-7,22-diene-3 β ,5 α ,6 α ,9 α -tetrol (21),^{2b)} (22*E*)-ergosta-7,22-diene-3 β ,5 α ,6 β ,9 α -tetrol (22),^{2a,10)} fasciculol B (23)^{13,14)} and fasciculol C (24)^{14,15)} from four edible mushrooms, *Panellus (P.) serotinus* (PERS.: FR.) KÜHN. (Mukitake in Japanese, Tricholomataceae, compounds 1, 2, 7–12, 19–21), *Lepista (L.) nuda* (BULL.: FR.) COOKE (Murasakishimeji in Japanese, Tricholomataceae, compounds 2, 13–22), *Tricholoma (T.) matsutake* (S. ITO et IMAI) SING. (Matsutake in Japanese, Tricholomataceae, compounds 2, 3) and *Naematoloma (N.) sublateritium* (FR.) KARST. (Kuritake in Japanese, Strophariaceae, compounds 4–6, 23, 24). This is the first time that compounds 7–12, 19–21, and compounds 13–22, have been isolated from *P. serotinus* and *L. nuda*, respectively. Extraction and isolation were carried out as described in the Experimental section.

Compound 1 was isolated as an amorphous powder, [α]_D +8.8°. The molecular formula was determined to be C₂₈H₄₄O₄ by high-resolution (HR)-MS, indicating seven degrees of unsaturation. The electron ionization (EI)-MS gave fragment ion peaks at *m/z* 317 [M⁺–side chain (s.c.)–2H], 299 (317–H₂O), 283 (M⁺–s.c.–2H₂O) and 257 [299–42 (ring

D)]. The ¹H-NMR spectrum (*vide* Experimental), obtained with the aid of a ¹H–¹H shift correlation spectroscopy (¹H–¹H COSY) spectrum, showed signals due to two tertiary methyl groups [δ _H 0.59 (3H, H₃-18), 1.20 (3H, H₃-19)], four secondary methyl groups [δ _H 0.82 (3H, H₃-26), 0.84 (3H, H₃-27), 0.92 (3H, H₃-28), 1.01 (3H, H₃-21)], two oxygenated methine protons [δ _H 3.89 (1H, H-3), 3.98 (1H, H-6)], two disubstituted olefinic protons [δ _H 5.15 (1H, H-22), 5.23 (1H, H-23)] and a trisubstituted olefinic proton [δ _H 5.31 (1H, H-7)]. The ¹³C-NMR spectrum (Table 1), obtained with the aid of a ¹H-detected heteronuclear multiple quantum coherence (HMQC) and a distortionless enhancement by polarization transfer (DEPT) spectra, revealed 28 carbon signals that included two oxygenated methine carbons [δ _C 66.6 (C-3), 73.0 (C-6)], two oxygenated quaternary carbons [δ _C 84.3 (C-9), 88.3 (C-5)] and four olefinic carbons [δ _C 123.2 (C-7), 132.4 (C-23), 135.2 (C-22), 141.6 (C-8)]. The IR absorption (3422 cm⁻¹) and the chemical shift values of two oxygenated methines [δ _H 3.89 (1H), 3.98 (1H); δ _C 66.6 (CH), 73.0 (CH)] indicated the presence of two secondary hydroxyl groups. The chemical shift values of two oxygenated quaternary carbons at δ _C 84.3 and 88.3 and the unsaturation degree indicated the presence of an epidioxy group. Based on these spectral data, 1 was suggested to be an ergostane-type sterol with two hydroxyl groups, one epidioxy group, one disubstituted double bond and one trisubstituted double bond. The ¹H–¹H COSY spectrum of 1 implied connectivities for H-3 to H₂-4 and H-6 to H-7 (Fig. 1). Interpretation of the ¹H-detected heteronuclear multiple bond connectivity (HMBC) spectrum revealed correlations between H-4 α to C-2, C-3, C-5 and C-10; H-7 to C-5, C-9 and C-14; H₃-18 to C-12, C-13, C-14 and C-17; H₃-19 to C-1, C-5, C-9 and C-10; H₃-21 to C-17, C-20 and C-22; H₃-26 and H₃-27 to C-24 and C-25; and H₃-28 to C-23, C-24 and C-25 (Fig. 1). Therefore, the planar structure of 1 was deduced to be 5,9-epidioxyergosta-7,22-diene-3,6-diol. The chemical shift value and the multiplicity of the hydroxy-bearing methine proton at C-3 [δ _H 3.89 (1H, m, *W*_{1/2} 22 Hz)] were those normally seen for 3 β -hydroxy-5 α -oxygenated A/B *trans* sterols.^{2,16)} This data indicated that the epidioxy group was assigned to be 5 α and 9 α . In the nuclear Overhauser effect correlation spectroscopy (NOESY) spectrum, a cross peak was observed between the

* To whom correspondence should be addressed. e-mail: mkikuchi@tohoku-pharm.ac.jp




Chart 1

H₃-19 and H-6 β , and the configuration of the hydroxyl group at C-6 was determined to be α (Fig. 2). The geometry of the Δ^{22} -double bond was deduced to be *E* from the ¹H-¹H coupling constant ($J=15.1$ Hz) between H-22 and H-23. The stereochemistry at C-20 and C-24 was determined to be *R* and *R*, respectively, by comparison of ¹H- and ¹³C-NMR data with those of ergosterol (**8**) (Table 2).¹⁷ The co-occurrence of **1** with **8** in the same mushroom indicates that the absolute structure of **1** is probably the same as **8**. Thus, the structure of **1** was determined to be 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 α -diol.

Compound **2** was isolated as an amorphous powder, $[\alpha]_D -24.4^\circ$. The molecular formula was determined to be C₂₈H₄₄O₄ by HR-MS. The IR spectrum showed the presence of a hydroxyl group (3410 cm⁻¹). The ¹³C-NMR spectrum of **2** was quite similar to that of **1**. The ¹H-NMR spectrum of **2** also showed a similar pattern to that of **1**, except for the chemical shifts of signals due to the hydroxy-bearing methine proton at C-6 and the trisubstituted olefinic proton at C-7. These data indicated that compound **2** was an epimer of **1** at C-6. In the ¹H-NMR spectrum, the chemical shift of the H₃-19 methyl group in pyridine-*d*₅ was shifted downfield by the pyridine-induced deshielding effect¹⁸ ($\delta_{C_5D_5N} - \delta_{CDCl_3}$; $\Delta\delta$, H₃-19, +0.32 ppm). This deshielding effect implies that the hydroxyl group at C-6 has a β configuration (Fig. 2). From the above data, the structure of **2** was determined to be 5 α ,9 α -epidioxy-(22*E*)-ergosta-7,22-diene-3 β ,6 β -diol. Compounds **1** and **2** have 5 α ,9 α -epidioxy-3 β ,6 α -dihydroxy-7-ene and 5 α ,9 α -epidioxy-3 β ,6 β -dihydroxy-7-ene moieties,

respectively, which are unprecedented in the natural sterols previously known.

Compound **3** was isolated as an amorphous powder, $[\alpha]_D -73.7^\circ$. The molecular formula was determined to be C₂₈H₄₄O₅ by HR-MS. The IR spectrum showed the presence of a hydroxyl group (3460 cm⁻¹) and a carbonyl group (1677 cm⁻¹). The ¹H-NMR spectrum showed signals due to two tertiary methyl groups [δ_H 0.99 (3H, H₃-19), 1.00 (3H, H₃-18)], four secondary methyl groups [δ_H 0.83 (3H, H₃-26), 0.85 (3H, H₃-27), 0.95 (3H, H₃-28), 1.00 (3H, H₃-21)], a hydroxy-bearing methine proton [δ_H 4.06 (1H, H-3)], two di-substituted olefinic protons [δ_H 5.34 (1H, H-23), 5.45 (1H, H-22)] and a trisubstituted olefinic proton [δ_H 6.50 (1H, H-7)]. The ¹³C-NMR spectrum revealed 28 carbon signals that included three oxygenated quaternary carbons [δ_C 75.9 (C-9), 79.3 (C-5), 84.6 (C-14)] and four olefinic carbons [δ_C 122.8 (C-7), 132.9 (C-23), 135.3 (C-22), 166.9 (C-8)]. The NMR data of **3** closely resembled those of **16** except for some signals surrounding C-14. The ¹H-¹H COSY, HMQC and HMBC data provided evidence of the same planar structure for **3** as that of **16**. The difference between **3** and **16** was traced to differences in the stereochemistry of the hydroxyl group at C-14. In the ¹H-NMR spectrum, the chemical shift of the H₃-18 methyl group in pyridine-*d*₅ was shifted downfield ($\delta_{C_5D_5N} - \delta_{CDCl_3}$; $\Delta\delta$, H₃-18, +0.33 ppm),¹⁸ indicating that the hydroxyl group at C-14 has a β configuration (Fig. 2). This was evident from the NOESY spectrum in pyridine-*d*₅, in which a cross-peak was seen between OH-14 and H₃-18 (Fig. 2). Thus, **3** was the epimer of **16** at C-14. Based on



Table 1. ^{13}C -NMR Chemical Shifts of Compounds 1–6

Position	1 ^{a,d}	2 ^{a,d}	3 ^{b,e}	4 ^{b,e}	5 ^{b,d}	6 ^{c,d}
1	28.9	28.7	26.0	126.5	50.7	45.1
2	30.8	31.7	31.7	146.9	211.5	69.5
3	66.6	66.8	66.7	200.9	83.3	84.0
4	34.1	34.8	38.1	44.5	45.2	40.2
5	88.3	86.6	79.3	48.4	50.0	50.6
6	73.0	72.2	199.4	18.8	18.8	24.2
7	123.2	122.5	122.8	25.9	26.5	124.6
8	141.6	141.8	166.9	136.2	136.1	143.6
9	84.3	84.7	75.9	131.2	132.2	148.9
10	54.2	51.0	43.3	39.1	43.3	39.8
11	22.8	23.1	28.0	34.4	33.0	118.0
12	36.6	36.6	37.4	73.1	73.0	76.1
13	42.1	41.9	49.8	50.9	50.4 ^f	48.5
14	52.1	52.1	84.6	50.5	50.4 ^f	51.1
15	23.1	23.2	41.9	32.2	32.3	33.7
16	28.2	28.1	28.6	28.2	28.3 ^g	28.5
17	55.5	55.5	56.1	38.7	38.6	40.0
18	11.6	11.7	17.5	17.2	16.9	17.6
19	16.2	17.3	22.9	24.4	20.0	24.1
20	40.3	40.4	39.5	44.1	44.0	44.3
21	21.1	21.1	20.4	61.2	61.2	62.1
22	135.2	135.2	135.3	28.3	28.3 ^g	28.1
23	132.4	132.3	132.9	29.8	29.8	29.3 ^h
24	42.8	42.8	43.3	79.1	79.0	79.4
25	33.1	33.1	33.4	72.8	72.7	73.9
26	19.6	19.7	19.9	26.1	26.1	25.7
27	20.0	20.0	20.2	26.0	25.9	24.9
28	17.6	17.6	17.9	26.8	29.1	29.3 ^h
29				21.8	17.1	17.7
30				23.9	24.0	28.7

a) Measurement in CDCl_3 . b) Measurement in $\text{C}_2\text{D}_5\text{N}$. c) Measurement in CD_3OD .
d) Measured at 100 MHz. e) Measured at 150 MHz. f–h) Signals overlapped.

this evidence, the structure of **3** was determined to be $3\beta,5\alpha,9\alpha,14\beta$ -tetrahydroxy-(22*E*)-ergosta-7,22-dien-6-one. Compound **3** is the first example of a naturally occurring $3\beta,5\alpha,9\alpha,14\beta$ -tetrahydroxy-7-en-6-one sterol.

Compound **4**, named sublateriol A, was isolated as an amorphous powder, $[\alpha]_D^{25} +82.4^\circ$. The molecular formula was determined to be $\text{C}_{30}\text{H}_{48}\text{O}_6$ by HR-MS. The IR spectrum showed the presence of a hydroxyl group (3425 cm^{-1}) and a carbonyl group (1672 cm^{-1}). The UV absorption maximum at 267 nm suggested a mono-enolized α -diketone.¹⁹ The ^1H -NMR spectrum showed signals due to seven tertiary methyl groups [δ_{H} 0.73 (3H, H₃-18), 1.14 (3H, H₃-29), 1.23 (3H, H₃-19), 1.25 (3H, H₃-28), 1.35 (3H, H₃-30), 1.50 (3H, H₃-27), 1.53 (3H, H₃-26)], two oxygenated methine protons [δ_{H} 3.86 (1H, H-24), 4.33 (1H, H-12)], an oxygenated methylene proton [δ_{H} 4.14 (2H, H-21)] and a trisubstituted olefinic proton [δ_{H} 6.81 (1H, H-1)]. The ^{13}C -NMR spectrum, obtained with the aid of HMQC and DEPT spectra, indicated the pres-

Fig. 1. ^1H - ^1H COSY and HMBC Correlations for **1**Fig. 2. NOEs and Pyridine-Induced Deshieldings for **1**–**3**Table 2. ^1H - and ^{13}C -NMR Chemical Shifts of the Side Chain of Compounds **1**, **4**, **8** and **24**^{a)}

Position	1 ^{b)}		8 ^{b)}		4 ^{c)}		24 ^{c)}	
	^1H	^{13}C	^1H ^{d)}	^{13}C ^{e)}	^1H	^{13}C	^1H ^{d)}	^{13}C ^{e)}
20		40.3		40.4		44.1		44.1
21	1.01 (d, 6.6)	21.1	1.04 (d, 6.6)	21.1	4.14 (br s)	61.2	4.12 (br s)	61.2
22	5.15 (dd, 15.1, 7.8)	135.2	5.16 (dd, 15.2, 7.4)	135.6	1.83 (m), 2.36 (m)	28.3	1.82 (m), 2.35 (m)	28.4
23	5.23 (dd, 15.1, 7.3)	132.4	5.23 (dd, 15.2, 6.9)	132.0	1.95 (2H, m)	29.8	1.94 (2H, m)	29.8
24		42.8		42.8	3.86 (br d, 9.5)	79.1	3.85 (dd, 9.9, 2.2)	79.1
25		33.1		33.1		72.8		72.8
26	0.82 (d, 6.6)	19.6	0.82 (d, 6.8)	19.7	1.53 (s)	26.1	1.52 (s)	26.1
27	0.84 (d, 6.8)	20.0	0.84 (d, 6.8)	20.0	1.50 (s)	26.0	1.49 (s)	26.0
28	0.92 (d, 6.8)	17.6	0.92 (d, 6.9)	17.6				

a) Figures in parentheses on ^1H -NMR denote J values (Hz). b) Measurement in CDCl_3 . c) Measurement in $\text{C}_2\text{D}_5\text{N}$. d) Measured at 600 MHz. e) Measured at 150 MHz.

ence of seven methyl, eight methylene, six methine and nine quarternary carbons. The IR absorption (3425 cm^{-1}) and the chemical shift values of two oxygenated methine [δ_{H} 3.86 (1H), 4.33 (1H); δ_{C} 73.1 (CH), 79.1 (CH)] and an oxygenated methylene [δ_{H} 4.14 (2H); δ_{C} 61.2 (CH₂)] indicated the presence of two secondary hydroxyl groups and a primary hydroxyl group. Detailed analysis of the ^1H - ^1H COSY spectrum of **4** implied connectivities for H-5 to H₂-7; H₂-11 to H-12; H₂-15 to H-17; H-17 to H-20; and H₂-21 to H-24 (Fig. 3). Interpretation of the HMBC spectrum revealed correlations from H-1 to C-2; H₃-18 to C-12, C-13, C-14 and C-17; H₃-19 to C-1, C-5, C-9 and C-10; H₃-26 and H₃-27 to C-24 and C-25; H₃-28 and H₃-29 to C-3, C-4 and C-5; and H₃-30 to C-8, C-13, C-14 and C-15 (Fig. 3). Therefore, the planar structure of **4** was deduced to be as shown in Fig. 3. The stereostructure was ascertained by NOE interactions observed in a NOESY spectrum (Fig. 4). The *trans*-junctions of rings A/B and rings C/D were based on NOESY correlations of H₃-28/H-5 α , H₃-28/H₃-29, H₃-29/H₃-19, H₃-19/H₃-18, H₃-18/H-15 β , H₃-18/H-16 β , and H₃-30/H-17 α . The hydroxyl group at C-12 has an α configuration, which was supported by the NOESY cross-peak between H-12 β and H₃-18. The stereochemistry at C-24 was determined to be *R* by comparison of ^1H - and ^{13}C -NMR data with those of fasciculol C (**24**) (Table 2). The absolute structure of fasciculol C (**24**) has been established by Ikeda *et al.*¹⁵) Fasciculols having the *R* configuration of the hydroxyl group at C-24 have been isolated from mushrooms belonging to the genus *Naematoloma*.^{13-15,20}) The *R* and *S* configuration of the hydroxyl group at C-24 of the side chain can be distinguished by NMR spectroscopy mainly by the chemical shift of the hydroxy-bearing methine at C-24.²¹) Based on this evidence, the structure of **4** was determined to be (2*R*)-2,12 α ,21,24,25-pentahydroxylanosta-1,8-dien-3-one.

Compound **5**, named sublateriol B, was isolated as an amorphous powder, $[\alpha]_{\text{D}} + 89.7^\circ$. The molecular formula was determined to be C₃₀H₅₀O₆ by HR-MS. The IR spectrum showed the presence of a hydroxyl group (3389 cm^{-1}) and a carbonyl group (1712 cm^{-1}). The ^1H - and ^{13}C -NMR data for **5** were quite similar to those of **4** except for the signals ascribed to ring A. The signals due to a methylene group [δ_{H} 2.44 (1H, H-1 α), 2.63 (1H, H-1 β); δ_{C} 50.7 (C-1)], an oxygenated methine group [δ_{H} 4.22 (1H, H-3); δ_{C} 83.3 (C-3)] and a carbonyl carbon [δ_{C} 211.5 (C-2)] were observed in the ^1H - and ^{13}C -NMR spectra of **5** instead of signals of the trisubstituted double bond between C-1 and C-2, and the carbonyl group at C-3 in **4**. The IR absorption (3389 cm^{-1}) and the chemical shift value of an oxygenated methine [δ_{H} 4.22 (1H); δ_{C} 83.3 (CH)] indicated the presence of a secondary hydroxyl group. In the HMBC spectrum, long-range ^1H - ^{13}C correlation of H₂-1 to C-2, as well as H₃-28 and H₃-29 to C-3, revealed that a carbonyl group and a hydroxyl group were attached to C-2 and C-3, respectively. The hydroxyl group at C-3 has a β configuration, which was supported by the NOESY cross-peaks between H-1 α and H-3 α ; H-3 α and H-5 α ; and H-3 α and H₃-28. Accordingly, the structure of **5** was determined to be (2*R*)-3 β ,12 α ,21,24,25-pentahydroxylanosta-8-en-2-one.

Compound **6**, named sublateriol C, was isolated as an amorphous powder, $[\alpha]_{\text{D}} + 63.4^\circ$. The molecular formula was determined to be C₃₀H₅₀O₆ by HR-MS [m/z 488 (M^+ -




Fig. 3. ^1H - ^1H COSY and HMBC Correlations for **4**




Fig. 4. NOEs Detected for **4**

H₂O]) and ^{13}C -NMR data. The IR spectrum showed the presence of a hydroxyl group (3430 cm^{-1}). The ^1H - and ^{13}C -NMR spectra of **6** were quite similar to those of **24**, except that **6** possesses signals of two trisubstituted double bonds [δ_{H} 5.55 (1H, H-11), 5.66 (1H, H-7); δ_{C} 118.0 (C-11), 124.6 (C-7), 143.6 (C-8), 148.9 (C-9)] instead of the signal of the fully substituted double bond between C-8 and C-9 in **24**. The HMBC correlations of H-11 to C-8, H-12 β to C-11, H₃-19 to C-9, and H₃-30 to C-8 implied the presence of a $\Delta^{7,9(11)}$ -diene system in **6**. This was evident from the UV absorption maxima at 237 (sh), 245 and 254 (sh) nm.¹⁹) Therefore, the structure of **6** was determined to be (2*R*)-lanosta-7,9(11)-diene-2 α ,3 β ,12 α ,21,24,25-hexaol.

Experimental

General Procedures Optical rotations were determined using a JASCO DIP-360 digital polarimeter. IR spectra were recorded with a Perkin-Elmer FT-IR 1725X IR spectrophotometer and UV spectra on a Beckman DU-64 spectrophotometer. ^1H - and ^{13}C -NMR spectra were recorded using JEOL JNM-LA 600 (600 and 150 MHz, respectively) and JEOL JNM-LA 400 (400 and 100 MHz, respectively) spectrometers. Chemical shifts are given on a δ (ppm) scale, with tetramethylsilane as an internal standard (s, singlet; d, doublet; dd, double doublet; ddd, double double doublet; br, broad; m, multiplet). The EI- and HR-MS were recorded on a JEOL JMS-DX 303 mass spectrometer. Column chromatography was carried out on Kieselgel 60 (Merck; 230-400 mesh). Preparative HPLC was carried out on a Tosoh HPLC system (pump, CCPD; detector, RI-8010) using a TSK gel ODS-120T (7.8 mm i.d. \times 30 cm) column (Tosoh). HPLC conditions: flow rate, 1.0 ml/min; column temperature, 40 $^\circ\text{C}$.

Material *Panellus serotinus* (from Morioka City in Iwate Prefecture, Japan), *Lepista nuda* (from Morioka City in Iwate Prefecture, Japan), *Tricholoma matsutake* (from Korea) and *Naematoloma sublateritium* (from Morioka City in Iwate Prefecture, Japan) were purchased in a food market.

Extraction and Isolation *P. serotinus*: The fresh fruit bodies of *P. serotinus* (1.1 kg) were extracted four times with Et₂O at room temperature for 2 weeks. The Et₂O extract (2.2 g) was chromatographed on a silica-gel column using *n*-hexane-EtOAc (7:3-1:7), EtOAc and MeOH, to afford 40 fractions (frs. 1-40). Fraction 6 was purified by preparative HPLC (mobile phase, MeOH) to give **7** (50.8 mg), **8** (587.0 mg), **9** (95.9 mg), **10** (39.5 mg), **11** (33.9 mg) and **12** (16.9 mg). Fraction 17 was purified by preparative HPLC (mobile phase, MeOH) to give **1** (1.1 mg). Fraction 20 was purified by preparative HPLC (mobile phase, MeOH) to give **2** (0.8 mg). Fraction 31 was purified by preparative HPLC [mobile phase, MeOH-H₂O (9:1)] to

give **19** (2.1 mg), **20** (0.4 mg) and **21** (0.3 mg).

L. nuda: The fresh fruit bodies of *L. nuda* (0.3 kg) were extracted four times with Et₂O at room temperature for 2 weeks. The Et₂O extract (1.4 g) was chromatographed on a silica-gel column using *n*-hexane–EtOAc (7:3—1:7), EtOAc and MeOH, to afford 29 fractions (frs. 1—29). Fraction 10 was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **13** (0.9 mg) and **15** (0.8 mg). Fraction 18 was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **2** (0.1 mg), **16** (0.1 mg), **17** (1.0 mg) and **18** (0.1 mg). Fraction 24 was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **19** (1.1 mg), **20** (0.2 mg) and **21** (0.2 mg). Fraction 25 was separated by preparative HPLC (mobile phase, MeOH) to give a mixture of **14** and **22**. This mixture was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **14** (0.1 mg) and **22** (0.7 mg).

T. matsutake: The fresh fruit bodies of *T. matsutake* (4.7 kg) were extracted four times with Et₂O at room temperature for 2 weeks. The Et₂O extract (8.7 g) was chromatographed on a silica-gel column using *n*-hexane–EtOAc (7:3—1:7), EtOAc and MeOH, to afford 31 fractions (frs. 1—31). Fraction 15 was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **2** (0.9 mg). Fraction 20 was purified by preparative HPLC [mobile phase, MeOH–H₂O (9:1)] to give **3** (1.0 mg).

N. sublateralium: The fresh fruit bodies of *N. sublateralium* (1.1 kg) were extracted four times with Et₂O at room temperature for 2 weeks. The Et₂O extract (5.9 g) was chromatographed on a silica-gel column using *n*-hexane–EtOAc (7:3—1:7), EtOAc and MeOH, to afford 60 fractions (frs. 1—60). Fraction 33 was purified by preparative HPLC [mobile phase, MeOH–H₂O (4:1)] to give **5** (1.5 mg). Fraction 37 was purified by preparative HPLC [mobile phase, MeOH–H₂O (4:1)] to give **23** (2.7 mg). Fraction 41 was purified by preparative HPLC [mobile phase, MeOH–H₂O (4:1)] to give **4** (0.9 mg). Fraction 50 was purified by preparative HPLC [mobile phase, MeOH–H₂O (7:2)] to give **6** (0.7 mg) and **24** (11.2 mg).

All known compounds (**7**—**24**) were identified by comparison of their chromatographic behavior, and their MS and ¹H-NMR data with those of the authentic samples (**7**—**22**) or by comparison of their physical data with reported values (**23** and **24**).

5 α ,9 α -Epidioxy-(22E)-ergosta-7,22-diene-3 β ,6 α -diol (1) Amorphous powder. [α]_D²⁵ +8.8° (*c*=0.1, CHCl₃). IR ν_{\max} CHCl₃ cm⁻¹: 3422. HR-MS *m/z*: 444.3242 (M⁺, Calcd for C₂₈H₄₄O₄: 444.3240). EI-MS *m/z*: (%): 444 (M⁺, 6), 317 (78), 299 (21), 283 (9), 257 (11). ¹H-NMR (400 MHz, CDCl₃) δ : 0.59 (3H, s, H₃-18), 0.82 (3H, d, *J*=6.6 Hz, H₃-26), 0.84 (3H, d, *J*=6.8 Hz, H₃-27), 0.92 (3H, d, *J*=6.8 Hz, H₃-28), 1.01 (3H, d, *J*=6.6 Hz, H₃-21), 1.20 (3H, s, H₃-19), 1.36 (1H, dd, *J*=14.4, 11.0 Hz, H-4 β), 1.94 (1H, d, *J*=8.5 Hz, OH-6), 2.02 (1H, m, H-20), 2.21 (1H, m, H-14), 2.60 (1H, ddd, *J*=14.4, 4.6, 2.2 Hz, H-4 α), 3.89 (1H, m, H-3), 3.98 (1H, dd, *J*=8.5, 2.4 Hz, H-6), 5.15 (1H, dd, *J*=15.1, 7.8 Hz, H-22), 5.23 (1H, dd, *J*=15.1, 7.3 Hz, H-23), 5.31 (1H, dd, *J*=2.4, 2.4 Hz, H-7). ¹³C-NMR (100 MHz, CDCl₃): see Table 1.

5 α ,9 α -Epidioxy-(22E)-ergosta-7,22-diene-3 β ,6 β -diol (2) Amorphous powder. [α]_D¹⁹ -24.4° (*c*=0.08, CHCl₃). IR ν_{\max} CHCl₃ cm⁻¹: 3410. HR-MS *m/z*: 444.3237 (M⁺, Calcd for C₂₈H₄₄O₄: 444.3240). ¹H-NMR (400 MHz, CDCl₃) δ : 0.63 (3H, s, H₃-18), 0.82 (3H, d, *J*=6.6 Hz, H₃-26), 0.84 (3H, d, *J*=6.6 Hz, H₃-27), 0.92 (3H, d, *J*=6.8 Hz, H₃-28), 1.01 (3H, d, *J*=6.8 Hz, H₃-21), 1.26 (3H, s, H₃-19), 1.66 (1H, d, *J*=6.6 Hz, OH-6), 2.24 (1H, m, H-14), 3.77 (1H, ddd, *J*=6.6, 4.4, 3.2 Hz, H-6), 4.03 (1H, m, H-3), 5.15 (1H, dd, *J*=15.1, 7.8 Hz, H-22), 5.23 (1H, dd, *J*=15.1, 7.3 Hz, H-23), 5.50 (1H, dd, *J*=4.4, 2.7 Hz, H-7); (400 MHz, C₅D₅N) δ : 0.68 (3H, s, H₃-18), 0.85 (3H, d, *J*=6.6 Hz, H₃-26), 0.86 (3H, d, *J*=6.8 Hz, H₃-27), 0.95 (3H, d, *J*=6.8 Hz, H₃-28), 1.03 (3H, d, *J*=6.6 Hz, H₃-21), 1.58 (3H, s, H₃-19), 2.52 (1H, ddd, *J*=14.1, 4.4, 1.7 Hz, H-4 α), 2.82 (1H, dd, *J*=14.1, 11.2 Hz, H-4 β), 4.26 (1H, m, H-6), 4.49 (1H, m, H-3), 5.17 (1H, dd, *J*=15.4, 8.3 Hz, H-22), 5.25 (1H, dd, *J*=15.4, 7.6 Hz, H-23), 5.82 (1H, dd, *J*=4.4, 2.9 Hz, H-7), 6.36 (1H, d, *J*=4.6 Hz, OH-3), 7.07 (1H, d, *J*=5.9 Hz, OH-6). ¹³C-NMR (100 MHz, CDCl₃): see Table 1.

3 β ,5 α ,9 α ,14 β -Tetrahydroxy-(22E)-ergosta-7,22-dien-6-one (3) Amorphous powder. [α]_D¹⁸ -73.7° (*c*=0.1, CHCl₃). IR ν_{\max} CHCl₃ cm⁻¹: 3460, 1677. UV λ_{\max} MeOH nm (log ϵ): 236 (3.7). HR-MS *m/z*: 460.3177 (M⁺, Calcd for C₂₈H₄₄O₅: 460.3189). ¹H-NMR (600 MHz, CDCl₃) δ : 0.83 (3H, d, *J*=6.6 Hz, H₃-26), 0.85 (3H, d, *J*=6.6 Hz, H₃-27), 0.95 (3H, d, *J*=6.6 Hz, H₃-28), 0.99 (3H, s, H₃-19), 1.00 (3H, s, H₃-18), 1.00 (3H, d, *J*=6.6 Hz, H₃-21), 2.33 (1H, ddd, *J*=13.9, 13.9, 4.0 Hz, H-1 α), 2.38 (1H, m, H-20), 2.80 (1H, m, H-15 α), 4.06 (1H, m, H-3), 5.34 (1H, dd, *J*=15.4, 8.1 Hz, H-23), 5.45 (1H, dd, *J*=15.4, 8.8 Hz, H-22), 6.50 (1H, s, H-7); (600 MHz, C₅D₅N) δ : 0.81 (3H, d, *J*=6.6 Hz, H₃-26), 0.82 (3H, d, *J*=6.6 Hz, H₃-27), 0.92 (3H, d, *J*=7.0 Hz, H₃-28), 1.12 (3H, d, *J*=6.6 Hz, H₃-21), 1.13 (3H, s, H₃-19),

1.33 (3H, s, H₃-18), 2.55 (1H, m, H-20), 2.84 (2H, m, H-1 α , H-4 α), 3.15 (1H, ddd, *J*=13.2, 13.2, 8.4 Hz, H-15 α), 4.64 (1H, m, H-3), 5.30 (1H, dd, *J*=15.4, 8.1 Hz, H-23), 5.61 (1H, dd, *J*=15.4, 8.1 Hz, H-22), 5.83 (1H, s, OH-14), 6.28 (1H, br s, OH-3), 6.52 (1H, s, OH-9), 7.14 (1H, s, H-7), 8.85 (1H, s, OH-5). ¹³C-NMR (150 MHz, C₅D₅N): see Table 1.

Sublateriol A (4) Amorphous powder. [α]_D³⁰ +82.4° (*c*=0.09, MeOH). IR ν_{\max} CHCl₃ cm⁻¹: 3425, 1672, 1656. UV λ_{\max} MeOH nm (log ϵ): 267 (3.7). HR-MS *m/z*: 504.3440 (M⁺, Calcd for C₃₀H₄₈O₆: 504.3451). ¹H-NMR (600 MHz, C₅D₅N) δ : 0.73 (3H, s, H₃-18), 1.14 (3H, s, H₃-29), 1.23 (3H, s, H₃-19), 1.24 (1H, m, H-15 α), 1.25 (3H, s, H₃-28), 1.35 (3H, s, H₃-30), 1.50 (3H, s, H₃-27), 1.52 (1H, m, H-16 β), 1.53 (3H, s, H₃-26), 1.63 (3H, m, H₂-6, H-20), 1.76 (1H, m, H-15 β), 1.83 (1H, m, H-22a), 1.95 (2H, m, H₂-23), 2.04 (1H, dd, *J*=11.4, 4.0 Hz, H-5), 2.10 (1H, m, H₂-7), 2.16 (1H, m, H-16 α), 2.36 (1H, m, H-22b), 2.62 (1H, br d, *J*=18.3 Hz, H-11 α), 2.90 (1H, m, H-17), 3.00 (1H, dd, *J*=18.3, 8.8 Hz, H-11 β), 3.86 (1H, br d, *J*=9.5 Hz, H-24), 4.14 (2H, br s, H₂-21), 4.33 (1H, br d, *J*=8.8 Hz, H-12), 5.54 (1H, br s, OH-25), 5.94 (1H, br s, OH-24), 6.05 (1H, d, *J*=2.6 Hz, OH-12), 6.81 (1H, s, H-1), 6.94 (1H, t, *J*=4.8 Hz, OH-21), 10.1 (1H, br s, OH-2). ¹³C-NMR (150 MHz, C₅D₅N): see Table 1.

Sublateriol B (5) Amorphous powder. [α]_D³² +89.7° (*c*=0.2, MeOH). IR ν_{\max} KBr cm⁻¹: 3389, 1712. HR-MS *m/z*: 506.3626 (M⁺, Calcd for C₃₀H₅₀O₆: 506.3607). ¹H-NMR (400 MHz, C₅D₅N) δ : 0.70 (3H, s, H₃-18), 0.92 (3H, s, H₃-29), 1.01 (3H, s, H₃-19), 1.33 (3H, s, H₃-28), 1.41 (3H, s, H₃-30), 1.49 (3H, s, H₃-27), 1.52 (3H, s, H₃-26), 1.87 (1H, dd, *J*=12.7, 2.0 Hz, H-5), 2.28 (1H, d, *J*=18.5 Hz, H-11 α), 2.44 (1H, d, *J*=12.0 Hz, H-1 α), 2.63 (1H, d, *J*=12.0 Hz, H-1 β), 2.73 (1H, dd, *J*=18.5, 8.5 Hz, H-11 β), 2.91 (1H, m, H-17), 3.85 (1H, br d, *J*=9.0 Hz, H-24), 4.13 (1H, br s, H₂-21), 4.22 (1H, d, *J*=3.7 Hz, H-3), 4.28 (1H, br d, *J*=9.3 Hz, H-12), 5.50 (1H, br s, OH-25), 5.89 (1H, br s, OH-24), 5.91 (1H, d, *J*=3.7 Hz, OH-3), 6.00 (1H, d, *J*=2.4 Hz, OH-12), 6.92 (1H, br s, OH-21). ¹³C-NMR (100 MHz, C₅D₅N): see Table 1.

Sublateriol C (6) Amorphous powder. [α]_D²⁸ +63.4° (*c*=0.07, MeOH). IR ν_{\max} CHCl₃ cm⁻¹: 3430. UV λ_{\max} MeOH nm (log ϵ): 237 sh (4.0), 245 (4.1), 254 sh (4.0). HR-MS *m/z*: 488.3532 (M⁺-H₂O, Calcd for C₃₀H₄₈O₅: 488.3502). ¹H-NMR (400 MHz, CD₃OD) δ : 0.62 (3H, s, H₃-18), 0.91 (3H, s, H₃-29), 1.03 (3H, s, H₃-28), 1.06 (3H, s, H₃-19), 1.13 (3H, s, H₃-30), 1.14 (3H, s, H₃-27), 1.17 (3H, s, H₃-26), 1.21 (1H, dd, *J*=11.2, 4.6 Hz, H-5), 1.43 (1H, dd, *J*=12.7, 12.2 Hz, H-1 α), 1.45 (3H, m, H-20, H-22, H-23), 1.50 (1H, m, H-15), 1.57 (1H, m, H-23), 1.75 (2H, m, H-15, H-16), 2.13 (3H, m, H₂-6, H-16), 2.33 (1H, dd, *J*=12.7, 4.4 Hz, H-1 β), 2.48 (1H, m, H-17), 2.94 (1H, d, *J*=9.5 Hz, H-3), 3.27 (1H, d, *J*=10.0 Hz, H-24), 3.70 (1H, m, H-2), 3.71 (1H, d, *J*=11.7 Hz, H-21a), 3.78 (1H, dd, *J*=11.7, 2.0 Hz, H-21b), 4.16 (1H, d, *J*=5.9 Hz, H-12), 5.55 (1H, br d, *J*=5.4 Hz, H-11), 5.66 (1H, br d, *J*=5.9 Hz, H-7). ¹³C-NMR (100 MHz, CD₃OD): see Table 1.

Acknowledgments We are grateful to Mr. S. Sato and Mr. T. Matsuki of this university for measurement of the mass and NMR spectra.

References and Notes

- Part XII in a series of studies on the constituents of mushrooms; Part XI: Ohnuma N., Yaoita Y., Kakuda R., Machida K., Kikuchi M., *J. Tohoku Pharmaceutical University*, "accepted".
- a) Ishizuka T., Yaoita Y., Kikuchi M., *Chem. Pharm. Bull.*, **45**, 1756—1760 (1997); b) Yaoita Y., Amemiya K., Ohnuma H., Furumura K., Masaki A., Matsuki T., Kikuchi M., *ibid.*, **46**, 944—950 (1998); c) Ishizuka T., Yaoita Y., Kikuchi M., *Natural Medicines*, **52**, 276—278 (1998); d) *Idem*, *Tohoku Yakka Daigaku Kenkyu Nempo*, **45**, 135—138 (1998); e) Yaoita Y., Endo M., Tani Y., Machida K., Amemiya K., Furumura K., Kikuchi M., *Chem. Pharm. Bull.*, **47**, 847—851 (1999); f) Ueno T., Yaoita Y., Kakuda R., Machida K., Kikuchi M., *J. Tohoku Pharmaceutical University*, **46**, 71—76 (1999); g) Ohnuma N., Amemiya K., Kakuda R., Yaoita Y., Machida K., Kikuchi M., *Chem. Pharm. Bull.*, **48**, 749—751 (2000).
- Yaoita Y., Machida K., Kikuchi M., *Chem. Pharm. Bull.*, **47**, 894—896 (1999).
- Yaoita Y., Ishizuka T., Kakuda R., Machida K., Kikuchi M., *Chem. Pharm. Bull.*, **48**, 1356—1358 (2000).
- Akihisa T., Hori T., Suzuki H., Sakoh T., Yokota T., Tamura T., *Phytochemistry*, **31**, 1769—1772 (1992).
- Shirane N., Takenaka H., Ueda K., Hashimoto Y., Katoh K., Ishii H., *Phytochemistry*, **41**, 1301—1308 (1996).
- Lenton J. R., Goad L. G., Goodwin T. W., *Phytochemistry*, **12**, 1135—1140 (1973).
- Arthur H. R., Halsall T. G., Smith R. D., *J. Chem. Soc.*, **1958**, 2603—

- 2605.
- 9) Wieland P., Prelog V., *Helv. Chim. Acta*, **30**, 1028—1030 (1947).
- 10) Valisolalao J., Luu B., Ourisson G., *Tetrahedron*, **39**, 2779—2785 (1983).
- 11) Alt G. H., Barton D. H. R., *J. Chem. Soc.*, **1954**, 1356—1361.
- 12) Iorizzi M., Minale L., Riccio R., Lee J., Yasumoto T., *J. Nat. Prod.*, **51**, 1098—1103 (1988).
- 13) Ikeda M., Watanabe H., Hayakawa A., Sato K., Sassa T., Miura Y., *Agric. Biol. Chem.*, **41**, 1543—1545 (1977).
- 14) Bernardi M. D., Mellerio G., Vidari G., Vita-Finzi P., Fronza G., Kocor M., Pyrek J. S., *J. Nat. Prod.*, **44**, 351—356 (1981); Kubo I., Matsumoto A., Kozuka M., Wood W. F., *Chem. Pharm. Bull.*, **33**, 3821—3825 (1985).
- 15) Ikeda M., Niwa G., Tohyama K., Sassa T., Miura Y., *Agric. Biol. Chem.*, **41**, 1803—1805 (1977).
- 16) Kobayashi M., Kanda F., *J. Chem. Soc., Perkin Trans. 1*, **1991**, 1177—1179.
- 17) Wright J. L. C., McInnes A. G., Shimizu S., Smith D. G., Walter J. A., *Can. J. Chem.*, **56**, 1898—1903 (1978).
- 18) Demarco P. V., Farkas E., Doddrell D., Mylari B. L., Wenkert E., *J. Am. Chem. Soc.*, **90**, 5480—5486 (1968).
- 19) Dorfman L., *Chem. Rev.*, **53**, 47—144 (1953).
- 20) Ikeda M., Sato Y., Izawa M., Sassa T., Miura Y., *Agric. Biol. Chem.*, **41**, 1539—1541 (1977); Takahashi A., Kusano G., Ohta T., Ohizumi Y., Nozoe S., *Chem. Pharm. Bull.*, **37**, 3247—3250 (1989).
- 21) Banskota A. H., Tezuka Y., Tran K. Q., Tanaka K., Saiki I., Kadota S., *J. Nat. Prod.*, **63**, 57—64 (2000).